EMA Revoked: Tavneos (avacopan) — Vifor Fresenius Medical Care Renal Pharma France

View source ↗

Summary

The EMA revoked Tavneos (avacopan) for its indications, including Microscopic Polyangiitis and Wegener Granulomatosis, effective January 15, 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microscopic Polyangiitis
• Wegener Granulomatosis

Drugs mentioned

• TAVNEOS (avacopan)

Snippet

Status: Revoked. Therapeutic area: Microscopic Polyangiitis;Wegener Granulomatosis. MAH: Vifor Fresenius Medical Care Renal Pharma France. Decision date: 15/01/2025. Orphan medicine